IP Library › Patent Application 18785056

Patent Application

App. No. 18/785,056

COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 18/785,056

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R 2 , R 3 , R 4 , Y 1 , Y 2 , X, and Z are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Claims (197)

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:

Y 1 is -Q-R 1 and Y 2 is R 2 ; or

Y 1 is R 2 and Y 2 is -Q-R 1 ;

wherein Q is a bond or —O—;

R 1 is phenyl substituted with 0-4 G groups;

each G is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R 5 , and alkoxy optionally substituted with one or more R 5 ;

each R 2 is independently H, halogen, —C(O)O-alkyl, or C 1 -C 3 alkyl optionally substituted with 1-3 halogens, provided that not more than one R 2 is —C(O)O-alkyl;

R 3 is H; halogen; alkenyl optionally substituted with cycloalkyl or heterocycloalkyl; heterocycloalkyl optionally substituted with —C(O)-alkyl; heterocycloalkenyl optionally substituted with C(O)-alkyl; heterocycloalkylalkyl optionally substituted with C(O)-alkyl; or heteroaryl optionally substituted with haloalkyl, cycloalkyl, or cycloalkylalkyl;

R 4 is H; alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)-alkyl, —C(O)-alkenyl, or —C(O)-cycloalkyl; or heterocycloalkylalkyl optionally substituted with —C(O)-alkyl, —C(O)—CH 2 —OH, or heteroaryl;

R 5 is halogen or OH;

X is —(CH 2 ) m —S(O) 2 —, —(CH 2 ) n —C(O)—, or —C(O)O—, wherein the right-hand side indicates the point of attachment to Z;

Z is —NR 6 R 7 , C 1 -C 6 alkyl optionally substituted with 1-4 R 8 , —C(CH 3 )═CH 2 , —CH 2 —CH═C═O, cycloalkyl optionally substituted with 1-4 R 9 , heterocycloalkyl optionally substituted with 1-4 R 10 , aryl optionally substituted with 1-4 R 10 , or heteroaryl optionally substituted with 1-4 R 10 ;

or X—Z is —C(═NR 7 ) 2 —NR 6 R 7 ;

or X is a bond and Z is a 5-6 membered heteroaryl optionally substituted with CN, —C(O)—NR 14 R 15 , —S(O) 2 —C 1 -C 3 alkyl, or —SO 2 —NR 14 R 15 ;

R 6 is hydrogen, —S(O) 2 —C 1 -C 3 alkyl, C 1 -C 6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each C 1 -C 6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with 1-3 R 11 ;

R 7 is hydrogen or C 1 -C 6 alkyl; or

R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocycloalkyl;

R 8 is —NR 6 R 7 , CN, hydroxy, alkoxy, haloalkoxy, —S—C 1 -C 3 alkyl, —S(O)—C 1 -C 3 alkyl, —S(O) 2 —C 1 -C 3 alkyl, —S(O) 2 —C 1 -C 3 haloalkyl, —S(O) 2 —NH 2 , —S(O)(NH)—C 1 -C 3 alkyl, —C(O)—NH 2 , —C(O)OH, —C(O)O—C 1 -C 3 alkyl, —C(O)C 1 -C 3 haloalkyl, —N(H)—C(O)—NR 6 R 7 , —N(H)—C(O)—C 1 -C 3 alkyl optionally substituted with —NR 12 R 13 or CN, —N(H)—C(O)—C 2 -C 6 alkenyl, —N(H)—C(O)—C 1 -C 3 haloalkyl, —N(H)—C(O)O—C 1 -C 6 alkyl, —N(H)—C(NH)—NH 2 , —N(H)—S(O) 2 —NR 12 R 13 , —N(R 7 )—S(O) 2 —C 1 -C 3 alkyl, —N(R 7 )—S(O) 2 -cycloalkyl, —N(H)—S(O) 2 —C 1 -C 3 haloalkyl, —P(O)(OH) 2 , —P(O)(C 1 -C 6 alkyl) 2 , cycloalkyl optionally substituted with 1-3 R 10 , heterocycloalkyl optionally substituted with 1-3 R 10 , or heteroaryl optionally substituted with 1-3 R 10 ; or

two R 8 , together with the carbon atom to which they are attached, join together to form a cycloalkyl;

each R 9 is independently CN, —S(O) 2 —C 1 -C 3 alkyl, or —N(C 1-3 alkyl) 2 ;

each R 10 is independently hydroxy, CN, C 1 -C 6 alkyl, haloalkyl, —NH 2 , —C(O)-alkenyl, —C(O)—NH 2 , —C(O)O-alkyl, —NH—C(O)-alkenyl, —S(O) 2 —C 1 -C 3 alkyl, —S(O) 2 —C 2 -C 6 alkenyl, or —S(O) 2 —NH 2 ;

each R 11 is independently hydroxy, CN, alkoxy, —S(O) 2 —C 1 -C 3 alkyl, or cycloalkyl;

each R 12 and R 13 are independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

each R 14 and R 15 are independently hydrogen or C 1 -C 6 alkyl;

n is 0, 1, or 2; and

m is 0, 1, 2, or 3;

provided that:

if Z is —C(CH 3 )═CH 2 , then X is —C(O)O— or n is 1 or 2 or m is 1, 2, or 3;

if X—Z is —C(O)—C 1 alkyl, R 8 cannot be CN, hydroxy, alkoxy, or haloalkoxy;

if X is —C(O)—, then Z cannot be oxiranyl;

if X is —C(O)— or —S(O) 2 —, Z is cycloalkyl substituted with one R 9 , and R 9 is CN, then R 9 cannot be attached to the same ring atom of Z as the atom to which X is attached;

if X is —C(O)— or —S(O) 2 —, Z is heterocycloalkyl substituted with one R 10 , and R 10 is hydroxy or CN, then R 10 cannot be attached to the same ring atom of Z as the atom to which X is attached; and

if X is —C(O)— or —S(O) 2 —, and Z is a partially saturated cycloalkyl or partially saturated heterocycloalkyl, a point of saturation of Z cannot be adjacent to X.

2 . The compound of claim 1 , wherein the compound is a compound of Formula (Ia):

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:

R 1 is phenyl substituted with 0-4 G groups;

each G is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R 5 , and alkoxy optionally substituted with one or more R 5 ;

each R 2 is independently H, halogen, —C(O)O-alkyl, or C 1 -C 3 alkyl optionally substituted with 1-3 halogens, provided that not more than one R 2 is —C(O)O-alkyl;

R 5 is halogen or OH;

X is —(CH 2 ) m —S(O) 2 —, —(CH 2 ) n —C(O)—, or —C(O)O—, wherein the right-hand side indicates the point of attachment to Z;

or X—Z is —C(═NR 7 ) 2 —NR 6 R 7 ;

or X is a bond and Z is a 5-6 membered heteroaryl optionally substituted with CN, —C(O)—NR 14 R 15 , —S(O) 2 —C 1 -C 3 alkyl, or —SO 2 —NR 14 R 15 ;

R 6 is hydrogen, C 1 -C 6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each C 1 -C 6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with 1-3 R 11 ;

R 7 is hydrogen or C 1 -C 6 alkyl; or

R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocycloalkyl;

two R 8 , together with the carbon atom to which they are attached, join together to form a cycloalkyl;

each R 9 is independently CN, —S(O) 2 —C 1 -C 3 alkyl, or —N(C 1-3 alkyl) 2 ;

R 11 is CN;

each R 12 and R 13 are independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

each R 14 and R 15 are independently hydrogen or C 1 -C 6 alkyl;

n is 0, 1, or 2; and

m is 0, 1, 2, or 3;

provided that:

if Z is —C(CH 3 )═CH 2 , then X is —C(O)O— or n is 1 or 2 or m is 1, 2, or 3;

if X—Z is —C(O)—C 1 alkyl, R 8 cannot be CN, hydroxy, alkoxy, or haloalkoxy;

if X is —C(O)—, then Z cannot be oxiranyl;

if X is —C(O)— or —S(O) 2 —, Z is cycloalkyl substituted with one R 9 , and R 9 is CN, then R 9 cannot be attached to the same ring atom of Z as the atom to which X is attached;

if X is —C(O)— or —S(O) 2 —, and Z is a partially saturated cycloalkyl or partially saturated heterocycloalkyl, a point of saturation of Z cannot be adjacent to X.

3 . The compound of claim 1 , wherein:

R 1 is phenyl substituted with 0-4 G groups;

each G is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R 5 , and alkoxy optionally substituted with one or more R 5 ;

each R 2 is independently H, halogen, —C(O)O-alkyl, or C 1 -C 3 alkyl optionally substituted with 1-3 halogens, provided that not more than one R 2 is —C(O)O-alkyl;

R 5 is halogen or OH;

X is —(CH 2 ) m —S(O) 2 —, —(CH 2 ) n —C(O)—, or —C(O)O—, wherein the right-hand side indicates the point of attachment to Z;

Z is —NR 6 R 7 , C 1 -C 6 alkyl optionally substituted with 1-4 R 8 , —CH 2 —CH═C═O, aryl optionally substituted with 1-4 R 10 , or heteroaryl optionally substituted with 1-4 R 10 ;

or X—Z is —C(═NR 7 ) 2 —NR 6 R 7 ;

or X is a bond and Z is a 5-6 membered heteroaryl optionally substituted with CN, —C(O)—NR 14 R 15 , —S(O) 2 —C 1 -C 3 alkyl, or —SO 2 —NR 14 R 15 ;

R 7 is hydrogen or C 1 -C 6 alkyl; or

R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocycloalkyl;

R 8 is —NR 6 R 7 , —S—C 1 -C 3 alkyl, —S(O)—C 1 -C 3 alkyl, —S(O) 2 —C 1 -C 3 alkyl, —S(O) 2 —C 1 -C 3 haloalkyl, —S(O) 2 —NH 2 , —S(O)(NH)—C 1 -C 3 alkyl, —C(O)—NH 2 , —C(O)OH, —C(O)O—C 1 -C 3 alkyl, —C(O)C 1 -C 3 haloalkyl, —N(H)—C(O)—NR 6 R 7 , —N(H)—C(O)—C 1 -C 3 alkyl optionally substituted with —NR 12 R 13 or CN, —N(H)—C(O)—C 2 -C 6 alkenyl, —N(H)—C(O)—C 1 -C 3 haloalkyl, —N(H)—C(O)O—C 1 -C 6 alkyl, —N(H)—C(NH)—NH 2 , —N(H)—S(O) 2 —NR 12 R 13 , —N(R 7 )—S(O) 2 —C 1 -C 3 alkyl, —N(R 7 )—S(O) 2 -cycloalkyl, —N(H)—S(O) 2 —C 1 -C 3 haloalkyl, —P(O)(OH) 2 , —P(O)(C 1 -C 6 alkyl) 2 , cycloalkyl optionally substituted with 1-3 R 10 , heterocycloalkyl optionally substituted with 1-3 R 10 , or heteroaryl optionally substituted with 1-3 R 10 ; or

two R 8 , together with the carbon atom to which they are attached, join together to form a cycloalkyl;

each R 9 is independently CN, —S(O) 2 —C 1 -C 3 alkyl, or —N(C 1 -3alkyl) 2 ;

R 11 is CN;

each R 12 and R 13 are independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

each R 14 and R 15 are independently hydrogen or C 1 -C 6 alkyl;

n is 0, 1, or 2; and

m is 0, 1, 2, or 3.

4 . The compound according to claim 1 , wherein:

R 1 is phenyl substituted 0-3 G 2 groups,

each G is independently selected from halogen, CN, and C 1 -C 3 alkyl optionally substituted with 1-3 R 5 ;

each R 2 is H, halogen, or CH 3 ;

R 5 is halogen or OH;

X is —(CH 2 ) m —S(O) 2 — or —(CH 2 ) n —C(O)—; and

Z is —NR 6 R 7 , C 1 -C 6 alkyl optionally substituted with 1-3 R 8 , cycloalkyl optionally substituted with 1-3 R 9 , heterocycloalkyl optionally substituted with 1-3 R 10 , aryl optionally substituted with 1-3 R 10 , or heteroaryl optionally substituted with 1-3 R 10 .

5 . The compound according to claim 4 , wherein:

R 1 is phenyl substituted 0-2 G groups,

each G is independently selected from Cl, F, CN, and C 1 -C 3 alkyl substituted with 1-3 R 5 ;

each R 2 is H, Cl, F, or CH 3 ; and R 5 is halogen.

6 . The compound of claim 5 , wherein R 5 is Cl or F.

7 . The compound of claim 1 , having one of the following formulae:

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIa) or (IIb); wherein:

each G is independently selected from Cl, F, CN, and C 1 -C 3 alkyl substituted with 1-3 R 5 ; and

R 5 is halogen.

8 . The compound according to claim 7 , having one of the following formulae:

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIIa), (IIIb), or (IIIc); wherein:

G is Cl, F, or CN.

9 . The compound of any one of claim 7 , wherein R 3 is H; halogen; C 2 -C 4 alkenyl optionally substituted with cyclopropyl or heterocycloalkyl; heterocycloalkyl optionally substituted with C(O)—CH 3 ; heterocycloalkenyl optionally substituted with C(O)—CH 3 ; heterocycloalkylalkyl optionally substituted with C(O)—CH 3 ; or 5-6 membered heteroaryl optionally substituted with haloalkyl, cyclopropyl, or cyclopropyl-CH 2 —.

10 . The compound of claim 7 , wherein R 4 is H; C 1 -C 3 alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)—CH 3 , —C(O)—CH═CH 2 , or —C(O)-cyclopropyl; heterocycloalkylalkyl optionally substituted with —C(O)—CH 3 ; —C(O)—CH 2 —OH; or 5-6 membered heteroaryl.

11 . The compound of claim 1 , having one of the following formulae:

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIIa), (IIIb), or (IIIc); wherein:

G is Cl, F, or CN;

R 3 is H; halogen; C 2 -C 4 alkenyl optionally substituted with cyclopropyl or heterocycloalkyl; heterocycloalkyl optionally substituted with C(O)—CH 3 ; heterocycloalkenyl optionally substituted with C(O)—CH 3 ; heterocycloalkylalkyl optionally substituted with C(O)—CH 3 ; or 5-6 membered heteroaryl optionally substituted with haloalkyl, cyclopropyl, or cyclopropyl-CH 2 —;

R 4 is H; C 1 -C 3 alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)—CH 3 —C(O)—CH═CH 2 , or —C(O)-cyclopropyl; heterocycloalkylalkyl optionally substituted with —C(O)—CH 3 ; —C(O)—CH 2 —OH; or 5-6 membered heteroaryl;

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is —NR 6 R 7 , C 1 -C 6 alkyl optionally substituted with 1-4 R 8 , C 3 -C 6 cycloalkyl optionally substituted with 1-4 R 9 , 5-10 membered heterocycloalkyl optionally substituted with 1-4 R 10 , C 6 -C 12 aryl optionally substituted with 1-4 R 10 , or 5-10 membered heteroaryl optionally substituted with 1-4 R 10 ;

or X is a bond and Z is a 5-6 membered heteroaryl optionally substituted with CN, —C(O)—NR 14 R 15 , —S(O) 2 —C 1 -C 3 alkyl, or —SO 2 —NR 14 R 15 ; and

n is 0, 1, or 2.

12 . The compound of claim 11 , wherein:

R 3 is H;

R 4 is H;

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is —NR 6 R 7 , C 1 -C 4 alkyl optionally substituted with 1-3 R 8 , C 3 -C 6 cycloalkyl optionally substituted with 1-3 R 9 , 5-7 membered heterocycloalkyl optionally substituted with 1-3 R 10 , C 6 -C 10 aryl optionally substituted with 1-3 R 10 , or 5-7 membered heteroaryl optionally substituted with 1-3 R 10 ; and

n is 0 or 1.

13 . The compound of claim 11 , wherein:

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is —NR 6 R 7 , C 2 -C 4 alkyl optionally substituted with 1-3 R 10 , C 6 -C 12 aryl optionally substituted with 1-3 R 10 , or 5-10 membered heteroaryl optionally substituted with 1-3 R 10 ; and

n is 0 or 1.

14 . The compound of claim 11 , wherein:

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is —NR 6 R 7 ; and

n is 0 or 1.

15 . The compound of claim 11 , wherein:

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is C 2 -C 4 alkyl optionally substituted with 1-3 R 8 ; and

n is 0 or 1.

16 . The compound of claim 11 , wherein:

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is C 6 -C 12 aryl optionally substituted with 1-3 R 10 ; and

n is 0 or 1.

17 . The compound of claim 11 , wherein:

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is 5-10 membered heteroaryl optionally substituted with 1-3 R 10 ; and

n is 0 or 1.

18 . The compound of claim 1 having one of the following formulae:

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIIa), (IIIb), or (IIIc); wherein:

G is Cl, F, or CN;

R 4 is H; C 1 -C 3 alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)—CH 3 , —C(O)—CH═CH 2 , or —C(O)-cyclopropyl; heterocycloalkylalkyl optionally substituted with —C(O)—CH 3 ; —C(O)—CH 2 —OH; or 5-6 membered heteroaryl;

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is —NR 6 R 7 , C 2 -C 4 alkyl optionally substituted with 1-3 R 8 , C 6 -C 12 aryl optionally substituted with 1-3 R 10 , or 5-10 membered heteroaryl optionally substituted with 1-3 R 10 ;

or X is a bond and Z is a 5-6 membered heteroaryl optionally substituted with CN, C(O)—NR 14 R 15 , —S(O) 2 —C 1 -C 3 alkyl, or —SO 2 —NR 14 R 15 ;

R 6 is hydrogen, C 1 -C 6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each C 1 -C 6 alkyl cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with 1-3 R 11 ;

R 7 is hydrogen or C 1 -C 6 alkyl; or

R 8 is —NR 6 R 7 , CN, hydroxy, alkoxy, haloalkoxy, —S—C 1 -C 3 alkyl, —S(O) 2 —C 1 -C 3 alkyl, —S(O) 2 —C 1 -C 3 haloalkyl, —S(O) 2 —NH 2 , —S(O)(NH)—C 1 -C 3 alkyl, —C(O)—NH 2 , —C(O)OH, —C(O)O—C 1 -C 3 alkyl, —C(O)C 1 -C 3 haloalkyl, —N(H)—C(O)—NR 6 R 7 , —N(H)—C(O)—C 1 -C 3 alkyl optionally substituted with —NR 12 R 13 or CN, —N(H)—C(O)—C 2 -C 6 alkenyl, —N(H)—C(O)—C 1 -C 3 haloalkyl, —N(H)—C(O)O—C 1 -C 6 alkyl, —N(H)—C(NH)—NH 2 , —N(H)—S(O) 2 —NR 12 R 13 , —N(R 7 )—S(O) 2 —C 1 -C 3 alkyl, —N(H)—S(O) 2 —C 1 -C 3 haloalkyl, —P(O)(OH) 2 , —P(O)(C 1 -C 6 alkyl) 2 , heterocycloalkyl optionally substituted with 1-3 R 10 , or heteroaryl optionally substituted with 1-3 R 10 ; or

two R 8 , together with the carbon atom to which they are attached, join together to form a cycloalkyl;

R 11 is CN;

each R 12 and R 13 are independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

each R 14 and R 15 are independently hydrogen or C 1 -C 6 alkyl; and

n is 0 or 1.

19 . The compound of claim 18 , wherein:

X is —S(O) 2 — or —C(O)—; and

Z is —(CH 2 ) 2 —S(O) 2 —CH 3 or —CH 2 —N(H)—C(O)—NH 2 .

20 . The compound of any one of claim 11 , wherein X is a bond and Z is a 5-6 membered heteroaryl optionally substituted with CN, C(O)—NR 14 R 15 , —S(O) 2 —C 1 -C 3 alkyl, or —SO 2 —NR 14 R 15 ; and each R 4 and R 15 are independently hydrogen or C 1 -C 3 alkyl.

21 . The compound of claim 1 , having one of the following formulae:

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IVa), (IVb), (IVc), (IVd), (IVe), or (IVf); wherein:

each G is independently selected from Cl, F, CN, and C 1 -C 3 alkyl substituted with 1-3 R 5 ; and

R 5 is halogen.

22 . The compound of claim 1 having one of the following formulae:

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (Va), (Vb), or (Vc); wherein:

G is Cl, F, or CN;

X is —S(O) 2 — or —(CH 2 ) n —C(O)—;

Z is —NR 6 R 7 , C 2 -C 4 alkyl optionally substituted with 1-3 R 8 , C 6 -C 12 aryl optionally substituted with 1-3 R 10 , or 5-10 membered heteroaryl optionally substituted with 1-3 R 10 ;

or X is a bond and Z is a 5-6 membered heteroaryl optionally substituted with CN, C(O)—NR 14 R 15 , —S(O) 2 —C 1 -C 3 alkyl, or —SO 2 —NR 14 R 15 ;

R 7 is hydrogen or C 1 -C 6 alkyl; or

two R 8 , together with the carbon atom to which they are attached, join together to form a cycloalkyl;

R 11 is CN;

each R 12 and R 13 are independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

each R 14 and R 15 are independently hydrogen or C 1 -C 6 alkyl; and

n is 0 or 1.

23 . The compound of claim 1 , wherein the compound is in the form of a formic acid salt.

24 . (canceled)

25 . (canceled)

26 . (canceled)

27 . A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier.

28 . The pharmaceutical composition of claim 27 , further comprising a second pharmaceutical agent.

29 . A method for treating a subject with a disease or condition mediated by YAP/TEAD, said method comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof.

30 . The method of claim 29 , wherein the disease or condition is a cancer, a neurodegenerative disease, a heart related disorder, or a kidney-related disorder.

31 . The method of claim 29 , wherein the disease or condition is polycystic kidney disease, Alzheimer's disease, arrhythmogenic cardiomyopathy, Holt-Oram syndrome, liver cancer, epithelioid hemangioendothelioma, breast cancer, lung cancer, malignant mesothelioma, pancreatic cancer, kaposi sarcoma, uveal melanoma, renal cell carcinoma, colorectal cancer, multiple myeloma, neurofibromatosis Type 2, glioma, or glioblastoma.

32 . The method of claim 29 , further comprising administering one or more additional therapeutic agents.

33 . The method according to claim 32 , wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent selected from adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan; ii) an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; iii) an antimetabolite selected from azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate; iv) an immune checkpoint agent selected from a PD-1 inhibitor, a PD-L1 inhibitor, and an anti-CTLA4 inhibitor; v) a hormone or hormone antagonist selected from enzalutamide, abiraterone, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; vi) a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel; vii) a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin; viii) an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine; ix) an antiangiogenic agent selected from AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; x) a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan, SN-38 (7-ethyl-10-hydroxy-camptothecin), rubitecan, topotecan, and 9-aminocamptothecin; xi) a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, 7-hydroxystaurosporine, and vatalanib; xii) a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin; xiii) a biological response modifier selected from imiquimod, interferon-α and interleukin-2; xiv) an IDO inhibitor; xv) a chemotherapeutic agent selected from 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, an mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor and an aromatase inhibitor (anastrozole letrozole exemestane); xvi) a BRAF inhibitor; xvii) a Mek inhibitor; xviii) c-Kit mutant inhibitor, xix) an EGFR inhibitor, xx) an epigenetic modulator; xxi) other adenosine axis blockade agents selected from CD39, CD38, A2AR and A2BR; or xxii) agonists of TNFA super family member; and xxiii) an anti-ErbB2 mAb.